COST OF CARE COMPARISON OF ELRANATAMAB-BCMM AND TECLISTAMAB-CQYV IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Shah, B. [1 ]
Sandin, R. [2 ]
Liu, Y. [3 ]
Hu, Y. [4 ]
Schepart, A. [5 ]
Hughes, D. [6 ]
Hart, J. [7 ]
Hlavacek, P. [7 ]
机构：
[1] Boston Med Ctr, Boston, MA USA
[2] Pfizer AB, Stockholm, Sweden
[3] Cytel, Rotterdam, Netherlands
[4] Ingress Hlth Cytel Co, Riverside, CA USA
[5] Pfizer Inc, New York, NY USA
[6] Pfizer Inc, Dorchester, MA USA
[7] Pfizer Inc, Boston, MA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE14
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT OF ELRANATAMAB-BCMM IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE UNITED STATES
    Shah, B.
    Sandin, R.
    Liu, Y.
    Hu, Y.
    Schepart, A.
    Hughes, D.
    Hart, J.
    Hlavacek, P.
    VALUE IN HEALTH, 2024, 27 (06) : S136 - S136
  • [2] Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma
    Moore, Donald C.
    Granger, Katelynn
    Hill, Hailey
    Karabinos, Allison
    Davis, James A.
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (06) : 197 - 200
  • [3] Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
    Maringanti, Sireesha Asoori
    Lin, Yi
    Estritis, Stathis
    Martinez-Lopez, Joaquin
    Bansal, Radhika
    Fotiou, Despina
    Corona, Magdalena
    Chhabra, Saurabh
    Brunaldi, Larissa
    Corraes, Andre De Menezes Silva
    Parrondo, Ricardo
    Kapoor, Prashant
    Ailawadhi, Sikander
    Mas, Reyes
    Tamayo, Andrea
    Dimopoulos, Meletios
    Durie, Brian
    Martin, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S506 - S507
  • [4] Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Martin, Thomas
    Wolf, Jeffrey
    Chung, Alfred
    Arora, Shagun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S536 - S537
  • [5] Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience
    Grajales-Cruz, Ariel F.
    Hansen, Doris K.
    Castaneda, Omar
    Graeter, Allison
    Vazquez-Martinez, Mariola A.
    Modukuri, Shrikar
    De Avila, Gabriel
    Denson, Ariel
    Fadul, Julia
    Blue, Brandon
    Lopez, Blanca
    Harvey, Kristy
    Thapa, Shrinjaya B.
    Tobon, Katherine
    Melnick, Parker
    Ionescu, Filip
    Liu, Hien
    Ochoa-Bayona, Jose L.
    Freeman, Ciara Louise
    Locke, Frederick
    Nishihori, Taiga
    Shain, Kenneth H.
    Alsina, Melissa
    Baz, Rachid
    BLOOD, 2024, 144 : 7832 - 7833
  • [6] Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Kastritis, Efstathios
    Brunaldi, Larissa
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Yong, Kwee
    Mactier, Catriona
    Corona, Magdalena
    Saez Marin, Adolfo Jesus
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Chhabra, Saurabh
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    BLOOD, 2023, 142
  • [7] Teclistamab for relapsed refractory multiple myeloma patients on dialysis
    Lebreton, P.
    Lachenal, F.
    Bouillie, S.
    Pica, G. M.
    Aftisse, H.
    Pascal, L.
    Montes, L.
    Macro, M.
    Johnson, N.
    Harel, S.
    Fernandez, M.
    De Renzis, B.
    Lioure, B.
    Lazareth, A.
    Javelot, M.
    Louni, C.
    Huart, A.
    Perrot, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 2077 - 2079
  • [8] Safety and efficacy of standard of care (SOC) teclistamab (TEC) in patients with relapsed/refractory multiple myeloma (RRMM), a single center experience
    Grajales-Cruz, Ariel
    Khadka, Sushmita
    Blue, Brandon
    Hansen, Doris
    Puglianini, Omar Castaneda
    Freeman, Ciara
    De Avila, Gabriel
    Ochoa-Bayona, Leonel
    Liu, Hien
    Nishihori, Taiga
    Locke, Frederick
    Shain, Ken
    Baz, Rachid
    Alsina, Melissa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S39 - S40
  • [9] Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    DerSarkissian, Maral
    Duh, Mei Sheng
    Lafeuille, Marie-Helene
    Posner, George
    Ralston, Stephen
    Zagadailov, Erin
    Ba-Mancini, Abbie
    Rifkin, Robert M.
    BLOOD, 2017, 130
  • [10] Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies
    Varshavsky-Yanovsky, Asya
    Jethava, Yogesh
    Stevens, Don A.
    Nooka, Ajay K.
    Stiff, Patrick J.
    Perez-Cruz, Isabel
    Leip, Eric
    Lesokhin, Alexander
    BLOOD, 2023, 142
12345